Palisade Bio (PALI) Net Income towards Common Stockholders (2010 - 2026)
Palisade Bio (PALI) posted quarterly Net Income towards Common Stockholders of -$10.7 million for Q1 2026, down 382.02% year-over-year from $3.8 million in Q1 2025, and down 7.64% quarter-over-quarter from -$10.0 million in Q4 2025.
Palisade Bio (PALI) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends
Palisade Bio (PALI) has reported Net Income towards Common Stockholders for 17 consecutive years, with -$10.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Income towards Common Stockholders fell 382.02% year-over-year to -$10.7 million; the TTM figure through Mar 2026 stood at -$26.4 million (down 100.13% YoY), while the FY2025 annual figure was -$45.3 million, up 4.19% from the prior year.
- Net Income towards Common Stockholders retreated to -$10.7 million in Q1 2026 per PALI's latest filing, from -$10.0 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at -$2.2 million in Q1 2025 and bottomed at -$10.7 million in Q1 2026.
- Historically, Net Income towards Common Stockholders has averaged -$4.1 million across 5 years, with a median of -$3.5 million in 2024.
- Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders jumped 92.62% — and 2026, when it sank 382.02%.
- Palisade Bio's Net Income towards Common Stockholders stood at -$3.8 million in 2022, then increased by 17.97% to -$3.2 million in 2023, then slipped by 7.28% to -$3.4 million in 2024, then slumped by 194.75% to -$10.0 million in 2025, then decreased by 7.64% to -$10.7 million in 2026.
- Business Quant data shows PALI's Net Income towards Common Stockholders at -$10.7 million in Q1 2026, -$10.0 million in Q4 2025, and -$2.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 930.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Palisade Bio | 372.94 Mn | 247.74 Mn | - | -11.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -11.70 Mn |
| Mar 31, 2026 | -10.75 Mn |
| Dec 31, 2025 | -9.99 Mn |
| Sep 30, 2025 | -2.87 Mn |
| Jun 30, 2025 | -2.78 Mn |
| Mar 31, 2025 | -2.23 Mn |
| Dec 31, 2024 | -3.39 Mn |
| Sep 30, 2024 | -3.49 Mn |
| Jun 30, 2024 | -4.08 Mn |
| Mar 31, 2024 | -3.53 Mn |
| Dec 31, 2023 | -3.16 Mn |
| Sep 30, 2023 | -3.80 Mn |
| Jun 30, 2023 | -3.39 Mn |
| Mar 31, 2023 | -2.34 Mn |
| Dec 31, 2022 | -3.85 Mn |
| Sep 30, 2022 | -4.50 Mn |
| Jun 30, 2022 | -2.34 Mn |
| Mar 31, 2022 | -3.93 Mn |
| Dec 31, 2021 | -1.70 Mn |
| Sep 30, 2021 | -3.04 Mn |